• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.

作者信息

Terlizzi V, Timpano S, Salvi M, Tosco A, Castaldo A, Fevola C, Leonetti G, Vitullo P, Sepe A, Badolato R, Salvatore D

机构信息

Department of Paediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Florence, Italy.

Cystic Fibrosis Regional Support Center, Department of Pediatrics, ASST Spedali Civili Brescia, University of Brescia, Brescia, Italy.

出版信息

J Cyst Fibros. 2023 Nov;22(6):1130-1132. doi: 10.1016/j.jcf.2023.06.013. Epub 2023 Jul 1.

DOI:10.1016/j.jcf.2023.06.013
PMID:37400299
Abstract
摘要

相似文献

1
Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡福妥治疗的囊性纤维化患者的高胆红素血症和吉尔伯特综合征
J Cyst Fibros. 2023 Nov;22(6):1130-1132. doi: 10.1016/j.jcf.2023.06.013. Epub 2023 Jul 1.
2
Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.病例系列报告：在存在吉尔伯特综合征的情况下，使用 elexacaftor/tezacaftor/ivacaftor 治疗导致高胆红素血症。
BMC Pulm Med. 2024 Jul 1;24(1):307. doi: 10.1186/s12890-024-03114-6.
3
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
4
Regarding the article entitled "Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis".关于题为《依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者肺功能年下降率的影响》的文章。
J Cyst Fibros. 2023 May;22(3):587. doi: 10.1016/j.jcf.2023.03.012. Epub 2023 Mar 21.
5
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
6
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
7
Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托在肝移植囊性纤维化患者中的应用。
J Cyst Fibros. 2022 Mar;21(2):227-229. doi: 10.1016/j.jcf.2021.07.017. Epub 2021 Aug 9.
8
Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡托治疗的成年囊性纤维化患者的睡眠特征
J Cyst Fibros. 2024 Jan;23(1):132-136. doi: 10.1016/j.jcf.2023.05.005. Epub 2023 May 19.
9
Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.接受依列卡福妥/替扎卡福妥/依伐卡托治疗的囊性纤维化患者不良事件的发生率：意大利托斯卡纳地区转诊中心的经验
Pediatr Pulmonol. 2023 Dec;58(12):3626-3629. doi: 10.1002/ppul.26673. Epub 2023 Sep 26.
10
Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.依列卡福妥/依伐卡托/替扎卡福妥所致药物性肝损伤
J Cyst Fibros. 2022 Mar;21(2):e99-e101. doi: 10.1016/j.jcf.2021.07.001. Epub 2021 Jul 16.

引用本文的文献

1
Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.在接受依列卡福/替扎卡福/依伐卡福治疗的囊性纤维化患者中，血小板减少可能取决于全身炎症的减轻。
Sci Rep. 2025 Jul 29;15(1):27571. doi: 10.1038/s41598-025-12333-8.
2
Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.接受CFTR调节剂治疗的囊性纤维化儿童的血红蛋白水平：一项单中心回顾性研究。
J Clin Med. 2025 Jul 9;14(14):4856. doi: 10.3390/jcm14144856.
3
Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.
囊性纤维化 F508del/CFTR 变异基因型患者接受依伐卡托/泰他卡托/艾氟卡托治疗后的肝生化指标和胆固醇代谢。
Sci Rep. 2024 Jul 29;14(1):17422. doi: 10.1038/s41598-024-68511-7.
4
Cystic fibrosis year in review 2023.囊性纤维化 2023 年年鉴
Pediatr Pulmonol. 2024 Dec;59(12):3106-3116. doi: 10.1002/ppul.27190. Epub 2024 Jul 26.
5
Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.病例系列报告：在存在吉尔伯特综合征的情况下，使用 elexacaftor/tezacaftor/ivacaftor 治疗导致高胆红素血症。
BMC Pulm Med. 2024 Jul 1;24(1):307. doi: 10.1186/s12890-024-03114-6.
6
Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight.囊性纤维化儿童和成人开始高效CFTR调节剂治疗后维生素和微量元素的变化——基于现实生活的洞察
Mol Cell Pediatr. 2024 May 8;11(1):4. doi: 10.1186/s40348-024-00178-6.
7
One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.在携带F508del突变纯合子的囊性纤维化患者中，使用依列卡福/替扎卡福/艾伐卡福治疗一年会导致肝脏生化指标显著升高。
Front Mol Biosci. 2024 Jan 8;10:1327958. doi: 10.3389/fmolb.2023.1327958. eCollection 2023.